Legal & General Group
CERE

Legal & General Group’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Legal & General Group’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-73,771
Closed -$3.02M – 3433
2024
Q2 		$3.02M Buy
73,771
+1,164
+2% +$48.5K ﹤0.01% 1764
2024
Q1 		$3.07M Buy
72,607
+2,106
+3% +$88.5K ﹤0.01% 1746
2023
Q4 		$2.99M Buy
70,501
+10,440
+17% +$300K ﹤0.01% 1749
2023
Q3 		$1.31M Buy
60,061
+2,538
+4% +$63.5K ﹤0.01% 2081
2023
Q2 		$1.83M Buy
57,523
+4,380
+8% +$134K ﹤0.01% 1968
2023
Q1 		$1.3M Buy
53,143
+2,537
+5% +$74.5K ﹤0.01% 2064
2022
Q4 		$1.6M Sell
50,606
-541
-1% -$15.3K ﹤0.01% 1975
2022
Q3 		$1.45M Buy
51,147
+4,531
+10% +$135K ﹤0.01% 2016
2022
Q2 		$1.23M Buy
46,616
+11,882
+34% +$337K ﹤0.01% 2078
2022
Q1 		$1.22M Buy
34,734
+18,146
+109% +$530K ﹤0.01% 2173
2021
Q4 		$538K Buy
16,588
+470
+3% +$16.6K ﹤0.01% 2388
2021
Q3 		$475K Buy
16,118
+9,821
+156% +$276K ﹤0.01% 2422
2021
Q2 		$161K Buy
+6,297
New +$90.1K ﹤0.01% 2594

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

Legal & General Group's CERE Position: Q3 2024 in Review

Legal & General Group sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 73,771 shares — an estimated $3.02M sold.

Legal & General Group first reported a position in CERE in Q2 2021 and held it in 13 quarters. The position peaked at $3.07M in Q1 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • Legal & General Group reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Legal & General Group sold 73,771 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $3.02M.
  • Legal & General Group first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q2 2021 and held it in 13 quarters.
  • Legal & General Group's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $3.07M in Q1 2024.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Legal & General Group's 13F filing for Q3 2024, filed 14 Nov 2024.